Alpha Teknova, Inc.

Equities

TKNO

US02080L1026

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 04:30:00 2024-05-03 pm EDT 5-day change 1st Jan Change
1.9 USD -1.81% Intraday chart for Alpha Teknova, Inc. +9.83% -49.06%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
BTIG Downgrades Alpha Teknova to Neutral From Buy MT
Transcript : Alpha Teknova, Inc., Q4 2023 Earnings Call, Mar 11, 2024
Alpha Teknova, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Alpha Teknova, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Earnings Flash (TKNO) ALPHA TEKNOVA Reports Q4 Revenue $7.9M, vs. Street Est of $8.3M MT
Alpha Teknova, Inc. Announces Impairment Charges for the Fourth Quarter Ended December 31, 2023 CI
Alpha Teknova, Inc. Provides Earnings Guidance for the Full Year 2024 CI
Alpha Teknova, Inc. Announces Termination of Certain Executive Officers, Effective from March 1, 2024 CI
Transcript : Alpha Teknova, Inc., Q3 2023 Earnings Call, Nov 09, 2023
Alpha Teknova, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Earnings Flash (TKNO) ALPHA TEKNOVA Posts Q3 Revenue $8.2M, vs. Street Est of $8.2M MT
Alpha Teknova, Inc. Provides Revenue Guidance for the Fiscal Year Ending December 31, 2023 CI
Alpha Teknova Insider Bought Shares Worth $1,499,999, According to a Recent SEC Filing MT
Alpha Teknova Closes Registered Direct Offering, Private Placement With Gross Proceeds of $22.9 Million MT
Alpha Teknova, Inc. announced that it has received $20.904987 million in funding CI
Alpha Teknova Expects $22.9 Million Gross Proceeds From Registered Direct Offering, Private Placement MT
Alpha Teknova, Inc. announced that it expects to receive $20.904987 million in funding CI
Alpha Teknova, Inc. Announces the Appointment of Martha J. Demski to Its Board of Directors CI
Alpha Teknova, Inc. Announces Executive Changes, Effective 31 , August 2023 CI
Transcript : Alpha Teknova, Inc., Q2 2023 Earnings Call, Aug 10, 2023
(TKNO) ALPHA TEKNOVA Forecasts Q2 Revenue $11.5M MT
Alpha Teknova, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Alpha Teknova, Inc. Provides Revenue Guidance for the Fiscal 2023 CI
Alpha Teknova, Inc. Announces the Opening of New GMP-Certified Production Facility CI
Alpha Teknova Initiated at Sector Weight by KeyBanc Amid Low-Single-Digit Near-Term Growth, Capital Raise Overhang MT
Chart Alpha Teknova, Inc.
More charts
Alpha Teknova, Inc. is a producer of critical reagents for the research, discovery, development, and commercialization of therapies, vaccines, and molecular diagnostics. It offers two primary business lines, which include lab essentials and clinical solutions. It also offers three primary product types: pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. The Company offers its liquid cell culture media and supplements and molecular biology reagents in both of its two product categories; pre-poured media plates are available in its Lab Essentials category only. Its customers include pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostics franchises, and academic and government research institutions developing vaccines and therapies and performing basic research.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.9 USD
Average target price
5.5 USD
Spread / Average Target
+189.47%
Consensus
  1. Stock Market
  2. Equities
  3. TKNO Stock
  4. News Alpha Teknova, Inc.
  5. Earnings Flash (TKNO) ALPHA TEKNOVA Posts Q3 Revenue $8.2M, vs. Street Est of $8.2M